GlassScriptPhysician profile
Daniel Frank Pauly
NPI 1003823329
$11,469.61
in general payments reported to CMS, 2019-2025
17 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2021: $1,083 · 2022: $7,499 · 2023: $445 · 2024: $987 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,000.07 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Triclip, Mitraclip |
| Abiomed | $443.57 | 2025 | |
| Ancora Heart, INC. | $416.21 | 2024-2025 | Accucinch |
| Boston Scientific Corporation | $306.22 | 2019-2025 | Resonate El Icd Vr |
| Cardiac Dimensions, INC. | $242.80 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $173.93 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.51 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $124.26 | 2024 | Nexletol, Nexlizet |
| Pfizer INC. | $115.39 | 2021-2025 | |
| Novo Nordisk INC | $113.39 | 2024 | |
| Merck Sharp & Dohme LLC | $113.33 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $103.23 | 2024 | |
| Cvrx, INC. | $96.69 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $38.57 | 2021 | |
| Medtronic Vascular, INC. | $23.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $19.12 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pauly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.